Monoclonal antibody-based candidate therapeutics against HIV type 1

AIDS Research and Human Retroviruses

Volumn 28, Issue 5, 2012, Pages 425-434

  Chen, Weizao ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IBALIZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY D5; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PG9; MONOCLONAL ANTIBODY VRC01; MONOCLONAL ANTIBODY VRC02; MONOCLONAL ANTIBODY Z13; MONOCLONAL ANTIBODY Z13E1; PRO 140; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; MACACA; MICE; NEUTRALIZATION TESTS;

EID: 84859504661     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0226     Document Type: Review

References (87)

1. Dimitrov DS and Marks JD: Therapeutic antibodies: Current state and future trends-is a paradigm change coming soon? Methods Mol Biol 2009;525:1-27, xiii.
2. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312. (Pubitemid 36378357)
3. Binley JM, Wrin T, Korber B, et al.: Comprehensive crossclade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004;78:13232-13252. (Pubitemid 39507829)
4. Chen W and Dimitrov DS: Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 2009;4:112-117.
5. Walker LM, Phogat SK, Chan-Hui PY, et al.: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-289.
6. Corti D, Langedijk JP, Hinz A, et al.: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010;5:e8805.
7. Wu X, Yang ZY, Li Y, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:856-861.
8. Chen W, Zhu Z, Feng Y, and Dimitrov DS: Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008;105:17121-17126.
9. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659. (Pubitemid 28289647)
10. Choudhry V, Zhang MY, Dimitrova D, et al.: Antibodybased inhibitors of HIV infection. Expert Opin Biol Ther 2006;6:523-531.
11. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rd, and Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68: 4821-4828. (Pubitemid 24226546)
12. Chen L, Kwon YD, Zhou T, et al.: Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009;326:1123-1127.
13. Zhang MY, Xiao X, Sidorov IA, et al.: Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 2004;78:9233-9242. (Pubitemid 39096533)
14. Zhang MY, Shu Y, Phogat S, et al.: Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003;283:17-25. (Pubitemid 37501056)
15. Parren PW, Ditzel HJ, Gulizia RJ, et al.: Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995; 9:F1-6.
16. Parren PW, Marx PA, Hessell AJ, et al.: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-8347. (Pubitemid 32743706)
17. Veazey RS, Shattock RJ, Pope M, et al.: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9:343-346. (Pubitemid 36362791)
18. Hessell AJ, Hangartner L, Hunter M, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449:101-104. (Pubitemid 47373775)
19. Cavacini LA, Samore MH, Gambertoglio J, et al.: Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1998;14:545-550. (Pubitemid 28196781)
20. Pegu A, Yang Z, Chen X, et al.: VRC01 provides sterilizing protection to non human primates from mucosal SHIV challenges. J Immunol 2011;186:155.11.
21. Buchacher A, Predl R, Strutzenberger K, et al.: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369. (Pubitemid 24141210)
22. Trkola A, Purtscher M, Muster T, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108. (Pubitemid 26029030)
23. Mascola JR, Lewis MG, Stiegler G, et al.: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009-4018. (Pubitemid 29189846)
24. Mascola JR, Stiegler G, VanCott TC, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210. (Pubitemid 30082367)
25. Hessell AJ, Rakasz EG, Poignard P, et al.: Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009;5:e1000433.
26. Li A, Baba TW, Sodroski J, et al.: Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses 1997;13:647-656. (Pubitemid 27210453)
27. Li A, Katinger H, Posner MR, et al.: Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu + by triple and quadruple combinations of human monoclonalantibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins. J Virol 1998;72:3235-3240. (Pubitemid 28175568)
28. Pejchal R, Gach JS, Brunel FM, et al.: A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 2009;83:8451-8462.
29. Alam SM, McAdams M, Boren D, et al.: The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007;178: 4424-4435. (Pubitemid 46492394)
30. Nelson JD, Brunel FM, Jensen R, et al.: An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007;81:4033-4043. (Pubitemid 46586898)
31. Zhu Z, Qin HR, Chen W, et al.: Cross-reactive HIV-1- neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol 2011, in press.
32. Armbruster C, Stiegler GM, Vcelar BA, et al.: A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002;16:227-233. (Pubitemid 34118570)
33. Ruprecht RM, Ferrantelli F, Kitabwalla M, Xu W, and McClure HM: Antibody protection: Passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003;21: 3370-3373. (Pubitemid 36792088)
34. Baba TW, Liska V, Hofmann-Lehmann R, et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-206. (Pubitemid 30082366)
35. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al.: Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003;17:301-309. (Pubitemid 36223254)
36. Armbruster C, Stiegler GM, Vcelar BA, et al.: Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/ 2G12. J Antimicrob Chemother 2004;54:915-920. (Pubitemid 39529987)
37. Trkola A, Kuster H, Rusert P, et al.: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005;11: 615-622. (Pubitemid 40868301)
38. Labrijn AF, Poignard P, Raja A, et al.: Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003;77:10557-10565. (Pubitemid 37129699)
39. Moulard M, Phogat SK, Shu Y, et al.: Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002;99:6913-6918. (Pubitemid 34526232)
40. Zhang MY, Shu Y, Rudolph D, et al.: Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 2004;335:209-219. (Pubitemid 37494973)
41. Zhang MY, Borges AR, Ptak RG, et al.: Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. MAbs 2010;2: 266-274.
42. Zhang C, Zheng J, Chen W, Dimitrov DS, and Goldstein H: Protective immunity: eAd inhibit in vivo HIV infection in humanized mice and can be expressed by lentiviral vectors to reprogram cells to secrete broadly neutralizing anti-HIV antibodies. 18th Conference on Retroviruses and Opportunistic Infections 2011; Abstracts: 379.
43. Jain RK and Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988;48:7022-7032. (Pubitemid 19013976)
44. Beckman RA, Weiner LM, and Davis HM: Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170-179. (Pubitemid 46106231)
45. Burkly LC, Olson D, Shapiro R, et al.: Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992;149:1779-1787.
46. Moore JP, Sattentau QJ, Klasse PJ, and Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4- induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992;66:4784-4793.
47. Reimann KA, Khunkhun R, Lin W, Gordon W, and Fung M: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002;18:747-755.
48. Reimann KA, Lin W, Bixler S, et al.: A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997;13:933-943. (Pubitemid 27334699)
49. Boon L, Holland B, Gordon W, et al.: Development of anti- CD4 MAb hu5A8 for treatment of HIV-1 infection: Preclinical assessment in non-human primates. Toxicology 2002;172:191-203. (Pubitemid 34219385)
50. Kuritzkes DR, Jacobson J, Powderly WG, et al.: Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004;189:286-291. (Pubitemid 38147253)
51. Trkola A, Ketas TJ, Nagashima KA, et al.: Potent, broadspectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75:579-588. (Pubitemid 32037260)
52. Olson WC, Rabut GE, Nagashima KA, et al.: Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999;73:4145-4155. (Pubitemid 29189860)
53. Jacobson JM, Saag MS, Thompson MA, et al.: Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008;198:1345-1352.
54. Mc Cann CM, Song RJ, and Ruprecht RM: Antibodies: Can they protect against HIV infection? Curr Drug Targets Infect Disord 2005;5:95-111. (Pubitemid 40974790)
55. Haynes BF, Fleming J, St Clair EW, et al.: Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005;308:1906-1908. (Pubitemid 40941873)
56. Matyas GR, Beck Z, Karasavvas N, and Alving CR: Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009;1788:660-665.
57. Xiao XD, Chen WZ, Feng Y, and Dimitrov DS: Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses-Basel 2009;1:802-817.
58. Huskens D, Van Laethem K, Vermeire K, Balzarini J, and Schols D: Resistance of HIV-1 to the broadly HIV-1- neutralizing, anti-carbohydrate antibody 2G12. Virology 2007;360:294-304. (Pubitemid 46482610)
59. Manrique A, Rusert P, Joos B, et al.: In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007;81:8793-8808. (Pubitemid 47242852)
60. Ichiyoshi Y and Casali P: Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med 1994;180:885-895. (Pubitemid 24256601)
61. Alam SM, Morelli M, Dennison SM, et al.: Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009;106:20234-20239.
62. Verkoczy L, Diaz M, Holl TM, et al.: Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010;107:181-186.
63. Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP, Jr., and Bjorkman PJ: Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci USA 2009;106:7385-7390.
64. Kunert R, Wolbank S, Stiegler G, Weik R, and Katinger H: Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti- HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004;20:755-762. (Pubitemid 39037507)
65. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, and Chen B: A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 2008;105:3739-3744. (Pubitemid 351723468)
66. Gustchina E, Bewley CA, and Clore GM: Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J Virol 2008;82:10032-10041.
67. Montgomery DL, Wang YJ, Hrin R, et al.: Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs 2009;1:462-474.
68. Hamburger AE, Kim S, Welch BD, and Kay MS: Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 2005;280:12567-12572.
69. Eckert DM, Shi Y, Kim S, et al.: Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci 2008;17:2091-2100.
70. Zhang MY, Vu BK, Choudhary A, et al.: Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J Virol 2008;82:6869-6879. (Pubitemid 351977708)
71. Choudhry V, Zhang MY, Sidorov IA, et al.: Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007; 363:79-90. (Pubitemid 46678166)
72. Zhang MY, Choudhry V, Sidorov IA, et al.: Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006;317:21-30. (Pubitemid 44822553)
73. Choudhry V, Zhang MY, Harris I, et al.: Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 2006;348: 1107-1115. (Pubitemid 44251203)
74. Beck Z, Prohaszka Z, and Fust G: Traitors of the immune system-enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development. Vaccine 2008;26:3078-3085.
75. Gao F, Scearce RM, Alam SM, et al.: Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 2009;394:91-98.
76. Sheppard NC, Davies SL, Jeffs SA, Vieira SM, and Sattentau QJ: Production and characterization of high-affinity human monoclonal antibodies to human immunodeficiency virus type 1 envelope glycoproteins in a mouse model expressing human immunoglobulins. Clin Vaccine Immunol 2007; 14:157-167. (Pubitemid 46407068)
77. Chen W, Zhu Z, Liao H, et al.: Cross-reactive human IgMderived monoclonal antibodies that bind to HIV-1 envelope glycoproteins. Viruses 2010;2:547-565.
78. Earl PL, Sugiura W, Montefiori DC, et al.: Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001;75:645-653. (Pubitemid 32037268)
79. Yang X, Wyatt R, and Sodroski J: Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001;75:1165-1171. (Pubitemid 32094675)
80. Jekle A, Chow E, Kopetzki E, et al.: CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Res 2009;83:257-266.
81. Ji C, Kopetzki E, Jekle A, et al.: CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J Biol Chem 2009;284:5175-5185.
82. Dey B, Del Castillo CS, and Berger EA: Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single- chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003;77:2859-2865. (Pubitemid 36228069)
83. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, and Berger EA: sCD4-17b bifunctional protein: Extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 2010;7:11.
84. West AP, Jr., Galimidi RP, Foglesong CP, Gnanapragasam PN, Klein JS, and Bjorkman PJ: Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J Virol 2010; 84:261-269.
85. Chen W, Xiao X, Wang Y, Zhu Z, and Dimitrov DS: Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 2010;88:107-115.
86. Forsman A, Beirnaert E, Aasa-Chapman MM, et al.: Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008;82:12069-12081.
87. Chen W, Feng Y, Gong R, et al.: Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 2011;85(18):9395-9405.